CAFC’s affirmation of PTAB Merck patent ruling raises questions

The US Court of Appeals for the Federal Circuit’s affirmation of the Patent Trial and Appeal Board’s (PTAB) decision to invalidate a Merck patent used to reduce homocysteine in the human body faced criticism from a dissenting judge, who claimed the court showed too much deference to the body’s decision.